Abstract
GnRH analogues afford effective, selective, reversible inhibition of pituitary gonadotropin secretion. We administered Buserelin (300 ug × 6/die) to 18 girls affected by precocious puberty, for 6-24 months (onset of first symptoms before 8 years of age). We evaluated Buserelin's effects on pituitary-gonadal, pituitary-thyroid, pituitary-adrenal Function, ultrasonographic pelvic organs and thermographic mammary patterns, clinical and auxological features.
Results: significant decreases (paired t test) were observed in: both LH and FSH reserves (LHRH test) and basal FSH since the First month (m) of treatment, E2 (3rd m), Progesterone (6th m); also TSH reserve (TRH test) since the 6th m, T3 (12th m) and fT3 (6th m) decreased significantly, though remaining in control range. 14, fT4, PRL, ACTH and adrenal hormones did not change significantly. Ultrasonography of the pelvis showed significant decreases of uterine (6th m) and ovarian (12th m) volume; the ovarian structure did not progress and follicle diameter uas always 9 mm. Clinical/thermographic evaluation oF the breast showed a generalized arrest or regression of its maturational patterns. Auxological data (slower bone maturation and growth velocity, lower SD scores For chronological and bone age, adult height prediction tending to improve) suggested a good prognosis. We conclude that these results of intranasal Buserelin administration and the absence of serious side effects make it advisable in the treatment of girls with true precocious puberty.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frejaville, E., Pifferi, C., Cesari, C. et al. 136 TREATMENT OF PRECOCIOUS PUBERTY BY INIRANASAL D-SER (TBU)6 LHRHI – 9EA10(BUSERELIN. Pediatr Res 24, 539 (1988). https://doi.org/10.1203/00006450-198810000-00157
Issue Date:
DOI: https://doi.org/10.1203/00006450-198810000-00157